Clinical trial
A Prospective, Multicenter, Single-Arm Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Ivonescimab in Unresectable, Non-Metastatic Hepatocellular Carcinoma
NCT06990620 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Single-Arm Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Ivonescimab in Unresectable, Non-Metastatic Hepatocellular Carcinoma
- Lead sponsor
- Fudan University
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- June 30, 2025
- Completion date
- December 31, 2027
- Enrollment
- 56 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hepatocellular carcinoma (hcc)